GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power SalesZacks Investment Research • 02/11/26
Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/11/26
Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/10/26
Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook?Investors Business Daily • 02/10/26
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 DividendBusiness Wire • 02/10/26
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 02/10/26
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILDZacks Investment Research • 02/10/26
FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System LymphomaBusiness Wire • 02/06/26
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/05/26
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to DeclineZacks Investment Research • 02/03/26